TY - JOUR
T1 - The EANM Focus 5 consensus on 'molecular imaging and theranostics in prostate cancer'
T2 - the future begins today
AU - Oprea-Lager, Daniela-Elena
AU - MacLennan, Steven
AU - Dierckx, Rudi
AU - Fanti, Stefano
PY - 2024/1/27
Y1 - 2024/1/27
N2 - After three years of COVID-pandemic, and in that setting an once postponed and eventually cancelled European Association of Nuclear medicine (EANM) Focus 4 on molecular imaging and therapy in haematological tumours [1], the Nuclear Medicine community felt the longing for a live consensus meeting, with multidisciplinary stakeholders. As the clinical evidence was pointing to Theranostics in prostate cancer to be the most dynamic and rapidly evolving field in Oncology in the past 5 years, the choice for a new focus topic was obvious.
AB - After three years of COVID-pandemic, and in that setting an once postponed and eventually cancelled European Association of Nuclear medicine (EANM) Focus 4 on molecular imaging and therapy in haematological tumours [1], the Nuclear Medicine community felt the longing for a live consensus meeting, with multidisciplinary stakeholders. As the clinical evidence was pointing to Theranostics in prostate cancer to be the most dynamic and rapidly evolving field in Oncology in the past 5 years, the choice for a new focus topic was obvious.
UR - http://www.scopus.com/inward/record.url?scp=85183396033&partnerID=8YFLogxK
U2 - 10.1007/s00259-023-06552-2
DO - 10.1007/s00259-023-06552-2
M3 - Editorial
C2 - 38280047
SN - 1619-7070
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
ER -
